Adalimumab is a recombinant human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-alpha). It has become an important drug in the treatment of inflammatory bowel diseases (IBD), which do not respond to initial medical treatment. The case of a patient with ulcerative proctitis is presented, who developed acute pleuropericarditis, after starting treatment with Adalimumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17235/reed.2024.10938/2024 | DOI Listing |
Publication Analysis
Top Keywords
acute pleuropericarditis
8
atypical side
4
side tnf
4
tnf alpha
4
alpha inhibitors
4
inhibitors acute
4
pleuropericarditis adalimumab
4
adalimumab recombinant
4
recombinant human
4
human monoclonal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!